Related Experiment Videos
Brain protection--human data and potential new therapies
L B Morgenstern1, L C Pettigrew
1Department of Neurology and The Epidemiology Research Center, University of Texas, Houston 77030, USA.
Abstract:
Neuroprotective therapy for acute ischemic stroke is the focus of considerable animal and human research. Several agents have progressed through human clinical trials and hold great promise both as single agents and adjuncts to thrombolytic therapy. Cytoprotective therapy is aimed at interfering with the ischemic cascade in penumbral tissue in regions of reduced cerebral blood flow. The ischemic cascade involves failure of adenosine triphosphate-driven ion pumps and consequent cell swelling and lactate accumulation. The cascade continues to involve excitatory amino acid-mediated injury which involves calcium dysregulation. Human studies which have progressed from previous animal work have focused on inhibiting excitatory amino acid-mediated injury, preventing free-radical effects, and blocking intracellular accumulation of calcium. The clinical use of these neuroprotective agents is definitely on the horizon, while active research continues.
Insights
Neuroprotective therapies aim to protect brain cells during acute ischemic stroke by interrupting the damaging cascade. Promising agents are nearing clinical use, offering new hope for stroke treatment alongside existing therapies.
Area of Science:
- Neurology
- Cerebrovascular Diseases
- Neuroprotection
Background:
- Acute ischemic stroke research focuses on neuroprotective therapies.
- Several agents show promise as standalone or adjunct treatments to thrombolysis.
- Cytoprotective therapy targets the ischemic cascade in penumbral tissue.
Purpose of the Study:
- To review the progress of neuroprotective agents for acute ischemic stroke.
- To highlight the mechanisms of the ischemic cascade and therapeutic targets.
- To discuss the potential clinical application of emerging neuroprotective strategies.
Main Methods:
- Review of animal and human research on neuroprotective agents.
- Analysis of therapeutic strategies targeting the ischemic cascade.
- Examination of clinical trial progress for neuroprotective agents.
Main Results:
- Neuroprotective agents target key steps in the ischemic cascade, including ion pump failure, excitotoxicity, and calcium influx.
- Human clinical trials have advanced for agents inhibiting excitatory amino acid injury, free radical damage, and calcium accumulation.
- These therapies hold significant promise for acute ischemic stroke management.
Conclusions:
- Neuroprotective agents are nearing clinical availability for acute ischemic stroke.
- Further research continues to refine these promising therapeutic strategies.
- The clinical use of neuroprotective agents is anticipated soon.